Showing results (21-30 of 107) with videos related to

Sort By:
Pageof 11
BMC Medical Genomics|April 30, 2014
Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcomeBrooke L Fridley, Sebastian M Armasu, Mine S Cicek, et al.
British Journal of Cancer|June 3, 2016
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancerChen Wang, Boris J Winterhoff, Kimberly R Kalli, et al.
European Journal of Human Genetics : EJHG|April 18, 2013
Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancerNicholas B Larson, Gregory D Jenkins, Melissa C Larson, et al.
International Journal of Molecular Epidemiology and Genetics|June 21, 2011
Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcomePrema Peethambaram, Brooke L Fridley, Robert A Vierkant, et al.
JCO Oncology Practice|May 20, 2022
Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort AnalysisChristopher S Strouse, Melissa C Larson, Shawna L Ehlers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2019
Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysisAngelo Fama, Melissa C Larson, Brian K Link, et al.
American Journal of Hematology|May 10, 2021
Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment eraNicholas J Boddicker, Melissa C Larson, Alessia Castellino, et al.
British Journal of Haematology|May 29, 2019
Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphomaYucai Wang, Matthew J Maurer, Melissa C Larson, et al.
Science Translational Medicine|January 14, 2026
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancerJulie R Duffield, Xiaonan Hou, Benjamin W Wilson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 2025
Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of OriginGeffen Kleinstern, Dennis P Robinson, Lisa M Rimsza, et al.
Pageof 11